Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.

Details

Language :

English

ISSN :

15560864

Volume :

18

Issue :

9

Database :

Complementary Index

Journal :

Journal of Thoracic Oncology

Publication Type :

Academic Journal

Accession number :

170044233

Full Text :

https://doi.org/10.1016/j.jtho.2023.05.015